Par Pharmaceutical, Sucampo, Takeda gastrointestinal news

Sucampo and Takeda filed suit in the U.S. District Court for the District of Delaware claiming that an ANDA from Par Pharmaceutical's Anchen Pharmaceuticals Inc. subsidiary for a generic version of Amitiza Lubiprostone infringes four U.S. patents scheduled to expire between 2020 and 2027. Sucampo and Takeda are seeking a declaration of infringement and to prevent approval and marketing of generic versions of Amitiza. Sucampo said the lawsuit prevents FDA from approving the ANDA for 30 months from Jan. 2, which is when Sucampo received notice from Anchen that the ANDA was filed. ...